

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

COLO 320

RRID:CVCL_1989

Type: Cell Line

Proper Citation

RRID:CVCL_1989

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1989

Proper Citation: RRID:CVCL_1989

Description: Cell line COLO 320 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colon adenocarcinoma

Defining Citation: [PMID:498117](#), [PMID:3629545](#), [PMID:6277475](#), [PMID:9000147](#), [PMID:9000572](#), [PMID:9023415](#), [PMID:9294210](#), [PMID:10737795](#), [PMID:11526487](#), [PMID:11668190](#), [PMID:11687795](#), [PMID:16854228](#), [PMID:20570890](#), [PMID:22460905](#), [PMID:24042735](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COLO 320

Synonyms: COLO-320, Colo-320, Colo 320, COLO #320, COLO320, Colo320, CoLo320, Co320, COLO 320F, Colorado 320

Cross References: BTO:BTO_0002047, CLO:CLO_0002571, CLO:CLO_0050628, EFO:EFO_0022664, CLDB:cl828, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN01821622, BioSample:SAMN03470903,

BioSample:SAMN10988542, cancercellines:CVCL_1989, CCRID:3101HUMTCHu14, Cell_Model_Passport:SIDM00071, ChEMBL-Cells:ChEMBL3307577, ChEMBL-Targets:ChEMBL614257, CLS:305271, ColonAtlas:COLO%20320, Cosmic:687518, Cosmic:711268, Cosmic:738934, Cosmic:873698, Cosmic:876712, Cosmic:887238, Cosmic:905008, Cosmic:913888, Cosmic:948129, Cosmic:948848, Cosmic:973606, Cosmic:995400, Cosmic:1057763, Cosmic:1122322, Cosmic:1132572, Cosmic:1154642, Cosmic:1184085, Cosmic:1187304, Cosmic:1479627, Cosmic:1609493, Cosmic:1676752, Cosmic:1805249, Cosmic:2550351, Cosmic:2800592, DepMap:ACH-000202, DSMZ:ACC-144, DSMZCellDive:ACC-144, EGA:EGAS00001000978, FANTOM5_SSTAR:10420-106C6, GEO:GSM794, GEO:GSM741256, GEO:GSM747237, GEO:GSM886941, GEO:GSM888008, GEO:GSM1448152, GEO:GSM1669684, GEO:GSM2549995, IARC_TP53:30025, LiGeA:CCLE_284, LINCS_LDP:LCL-1174, MetaboLights:MTBLS227, PharmacnoDB:COLO320_222_2019, Progenetix:CVCL_1989, PubChem_Cell_line:CVCL_1989, RCB:RCB1193, Wikidata:Q54814087

ID: CVCL_1989

Record Creation Time: 20220427T215514+0000

Record Last Update: 20260920T001842+0000

Ratings and Alerts

No rating or validation information has been found for COLO 320.

No alerts have been found for COLO 320.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cao D, et al. (2026) Mutant KRAS Suppresses DNA Sensing by Remodeling Membrane Tension to Clear Extracellular Tumor DNA. Cancer research, 86(14), 3394.

Kim H, et al. (2026) Increased vulnerability of colorectal cancer models with high alkylation damage to NTHL1 inactivation. Scientific reports, 16(1).

Nakayama M, et al. (2025) Missense Mutant p53 Transactivates Wnt/??-Catenin Signaling in Neighboring p53-Destabilized Cells through the COX-2/PGE2 Pathway. Cancer research communications, 5(1), 13.

Qin LN, et al. (2025) Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARYlation complex. Molecular cell, 85(16), 3090.

Clarkson E, et al. (2025) BMP antagonist CHRDL2 enhances the cancer stem-cell phenotype and increases chemotherapy resistance in colorectal cancer. *Molecular oncology*, 19(11), 3135.

Champagne J, et al. (2025) Adoptive T^{reg} cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Guo X, et al. (2024) CD24-Targeted NIR-II Fluorescence Imaging Enables Early Detection of Colorectal Neoplasia. *Cancer research*, 84(23), 4099.

Tian J, et al. (2024) ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms. *Cancer immunology research*, 12(5), 592.

Lee CT, et al. (2023) Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer. *Molecular carcinogenesis*.

Guo X, et al. (2023) NIR-II fluorescence imaging-guided colorectal cancer surgery targeting CEACAM5 by a nanobody. *EBioMedicine*, 89, 104476.

Liu C, et al. (2023) Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. *Cell reports*, 42(4), 112401.

Vienot A, et al. (2023) SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features. *Molecular oncology*, 17(7), 1356.

Sun L, et al. (2023) USP10 Regulates ZEB1 Ubiquitination and Protein Stability to Inhibit ZEB1-Mediated Colorectal Cancer Metastasis. *Molecular cancer research : MCR*, 21(6), 578.

Lier S, et al. (2022) A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. *Bioorganic chemistry*, 119, 105505.

Dieter SM, et al. (2021) Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. *Cell reports*, 36(3), 109394.

Nagasawa I, et al. (2020) Identification of a Small Compound Targeting PKM2-Regulated Signaling Using 2D Gel Electrophoresis-Based Proteome-wide CETSA. *Cell chemical biology*, 27(2), 186.

Galaine J, et al. (2019) CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. *International journal of cancer*, 145(11), 3112.